CMEA Ventures
VC Fund
San Francisco, United States
CMEA Ventures is a San Francisco based venture capital firm that specializes in high technology, life sciences, and alternative energy investments. The firm invests in both early and late stage companies, and actively partners with its extended network of companies, other VC firms, institutional investors, strategic partners as well asentrepreneurs. CMEA was originally formed as an affiliate of New Enterprise Associates (NEA) in 1989 and became independent in 1997. CMEA currently has 74 portfolio companies, 6 funds and manages $1.2 billion of venture capital.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries CMEA Ventures invests in
Stages CMEA Ventures invests in
Countries CMEA Ventures invests in
Investment Focus
Industry
- Health Care 11 (29%)
- Biotechnology 10 (26%)
- Pharmaceutical 6 (16%)
- Medical 4 (11%)
- Software 4 (11%)
Stage
- Series C 12 (32%)
- Series B 11 (29%)
- Series A 6 (16%)
- Funding Round 3 (8%)
- Private Equity 3 (8%)
Country
- United States 23 (61%)
- Canada 1 (3%)
- Singapore 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Odyssey Logistics & Technology Corporation (Odyssey) is a global logistics solutions provider with a freight network exceeding $3B globally. Odyssey improves its customers’ supply chain performance through a proprietary, predictive global technology platform, an international network of logistics engineering experts and specialized processesthat drive quality, safety and sustainability. Its Door-To-Done® approach to complex global logistics helps ensure products are delivered through a safe, secure and environmentally responsible system. In addition to being certified by the American Chemistry Council as a Responsible Care® partner company and a leader in Jones Act transportation, Odyssey offers a broad portfolio of services including intermodal, over-the-road trucking, warehousing, global forwarding, managed services and consulting. Serving multifaceted, intricate logistics needs, Odyssey operates in high-barrier-to-entry markets with specialized transportation services that include bulk truck, ISO Tank, railcar and tanker, as well as food-grade product lines. Odyssey also prioritizes giving back to the community by supporting various organizations, including Project Outreach and Junior Achievement®. For more information on Odyssey, visit www.odysseylogistics.com. | $40M / Sep 04, 2014 | |
|
|
Odyssey Logistics & Technology Corporation (Odyssey) is a global logistics solutions provider with a freight network exceeding $3B globally. Odyssey improves its customers’ supply chain performance through a proprietary, predictive global technology platform, an international network of logistics engineering experts and specialized processesthat drive quality, safety and sustainability. Its Door-To-Done® approach to complex global logistics helps ensure products are delivered through a safe, secure and environmentally responsible system. In addition to being certified by the American Chemistry Council as a Responsible Care® partner company and a leader in Jones Act transportation, Odyssey offers a broad portfolio of services including intermodal, over-the-road trucking, warehousing, global forwarding, managed services and consulting. Serving multifaceted, intricate logistics needs, Odyssey operates in high-barrier-to-entry markets with specialized transportation services that include bulk truck, ISO Tank, railcar and tanker, as well as food-grade product lines. Odyssey also prioritizes giving back to the community by supporting various organizations, including Project Outreach and Junior Achievement®. For more information on Odyssey, visit www.odysseylogistics.com. | $20M / Dec 23, 2010 | |
|
|
Solyndra is a manufacturer of cylindrical panels of CIGS thin-film solar cells based in Fremont, California.Solyndra designs and manufactures photovoltaic systems, comprised of panels and mounting hardware, for the commercial rooftop market. Solyndra employs high volume manufacturing based on proven technologies and processes to meet the needsof the global solar market. Using proprietary cylindrical modules and thin-film technology, Solyndra systems are designed to provide the lowest installed cost per system and the highest solar electrical energy output for typical low slope commercial rooftops. Founded in 2005 and headquartered in Fremont, California, Solyndra operates a state-of-the-art 300,000 square foot fully-automated manufacturing complex. | $175M / Private Equity / Jun 18, 2010 | |
|
|
Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories. | $25M / Series B / Sep 22, 2009 | |
|
|
Arcadia Biosciences is an agricultural technology company focused on developing products that benefit the environment and human health. The company uses advanced screening, breeding and biotechnology techniques (both GM and non-GM) to create value for consumers, processors and farmers. | $15M / Private Equity / Oct 31, 2008 | |
|
|
VeraLight is a medical device company that was established in October 2004 to focus on a comprehensive approach to non-invasive type 2 diabetes and pre-diabetes screening with the proprietary SCOUT DS® system. Their mission is to help stem the tide of the worldwide diabetes epidemic by driving early diabetes detection, thus enabling initiation oftherapies that can prevent diabetes or reduce its complications. The company develops and acquires intellectual property, products, and services that contribute to this mission. | $20M / Series C / Jun 03, 2008 | |
|
|
NOVX Systems provides a complete and powerful point-of-collection drug screening solution Get Accurate On-site Results See the Complete Case History Scale without Complexity | $7.8M / Series C / May 02, 2008 | |
|
|
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietaryDNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry. | $15M / Series B / Nov 12, 2007 | |
|
|
Odyssey Logistics & Technology Corporation (Odyssey) is a global logistics solutions provider with a freight network exceeding $3B globally. Odyssey improves its customers’ supply chain performance through a proprietary, predictive global technology platform, an international network of logistics engineering experts and specialized processesthat drive quality, safety and sustainability. Its Door-To-Done® approach to complex global logistics helps ensure products are delivered through a safe, secure and environmentally responsible system. In addition to being certified by the American Chemistry Council as a Responsible Care® partner company and a leader in Jones Act transportation, Odyssey offers a broad portfolio of services including intermodal, over-the-road trucking, warehousing, global forwarding, managed services and consulting. Serving multifaceted, intricate logistics needs, Odyssey operates in high-barrier-to-entry markets with specialized transportation services that include bulk truck, ISO Tank, railcar and tanker, as well as food-grade product lines. Odyssey also prioritizes giving back to the community by supporting various organizations, including Project Outreach and Junior Achievement®. For more information on Odyssey, visit www.odysseylogistics.com. | $5M / Series C / Sep 26, 2007 | |
|
|
NOVX Systems provides a complete and powerful point-of-collection drug screening solution Get Accurate On-site Results See the Complete Case History Scale without Complexity | $2.7M / Debt Financing / Aug 03, 2007 | |
| See all 38 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does CMEA Ventures invest in?
CMEA Ventures invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series C and Series B stage. Most of the 38 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did CMEA Ventures last invest?
The most recent investment recorded for CMEA Ventures closed in Sep 2014. Shizune tracks 38 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!